Skip to content

Study · Animal study (in vivo) · mouse and rat · 2007

3 results

[Manifestations of the antinociceptive and anxiolytic properties of the compound GB-115: interactions of cholecystokinin and opioid systems].

Kolik LG, Zhukov VN, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2007Cited by 1 (Europe PMC)

PMID17523442 (opens in a new tab)PepBankPUB-17523442
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, GB‑115 significantly increased hot plate response latency independently of naloxone.

    In plain wordsIn mice, GB‑115 increased hot plate response time independently of naloxone.

    Peptide
    GB-115
    Outcome
    IncreaseHot plate response latency
    Study

    mousen: not reported in source

    Hot plate test
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    It s established that GB-115 (4 mg/kg) significantly increases the response latency in naloxone-independent manner in the "hot plate" test in mice and produced a moderate naloxone-reversible analgesic effect in the "tail flick" test in mice.
    1 context sentence
    Summary · context
    The antinociceptive and anxiolytic properties of the new drug GB-115 (0.0125-4 mg/kg, i.p.), which is a short peptide antagonist of CCK2-receptors, have been studied in rats and mice using thermal models of nociception and the standard "elevated plus-maze" (EPM) test for measuring anxiety.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, GB‑115 produced a moderate analgesic effect in the tail flick test that naloxone reversed.

    In plain wordsIn mice, GB‑115 moderately reduced the tail flick pain response, and naloxone reversed this effect.

    Peptide
    GB-115
    Outcome
    DecreaseTail flick pain response
    Study

    mousen: not reported in source

    Tail flick test
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    4 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    It s established that GB-115 (4 mg/kg) significantly increases the response latency in naloxone-independent manner in the "hot plate" test in mice and produced a moderate naloxone-reversible analgesic effect in the "tail flick" test in mice.
    1 context sentence
    Summary · context
    The antinociceptive and anxiolytic properties of the new drug GB-115 (0.0125-4 mg/kg, i.p.), which is a short peptide antagonist of CCK2-receptors, have been studied in rats and mice using thermal models of nociception and the standard "elevated plus-maze" (EPM) test for measuring anxiety.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, opioid receptor blockade with naloxone did not influence the anxiolytic effects of GB‑115.

    In plain wordsIn rats, naloxone did not change the anxiety-reducing effects of GB‑115.

    Peptide
    GB-115
    Outcome
    No significant changeAnxiolysis during opioid receptor blockade
    Study

    ratn: not reported in source

    Elevated plus-maze with naloxone
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.025 and 4 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The blocking of opioid receptors by naloxone does not influence the anxiolytic effects of GB-115 (0.025 and 4 mg/kg) in the EPM test on rats.
    1 context sentence
    Summary · context
    The antinociceptive and anxiolytic properties of the new drug GB-115 (0.0125-4 mg/kg, i.p.), which is a short peptide antagonist of CCK2-receptors, have been studied in rats and mice using thermal models of nociception and the standard "elevated plus-maze" (EPM) test for measuring anxiety.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.